Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671224 | 0.90 | PLA2G10 (0.40) | PLA2G10PLA2G5KDM4EALDH1A1CNR1 | |
| SCHEMBL3470166 | 0.85 | PLA2G10 (0.41) | PLA2G10PLA2G5KDM4EALDH1A1CHRM2 | |
| SCHEMBL27147241 | 0.85 | PLA2G10 (0.41) | PLA2G10PLA2G5KDM4EALDH1A1CHRM2 | |
| SCHEMBL3799622 | 0.85 | PLA2G10 (0.41) | PLA2G10PLA2G5KDM4EALDH1A1CHRM2 | |
| SCHEMBL4133149 | 0.83 | CNR1 (0.39) | PLA2G10PLA2G5KDM4EALDH1A1CNR1 | |
| SCHEMBL18362392 | 0.81 | ATM (0.40) | PLA2G10PLA2G5KDM4EALDH1A1CNR1 | |
| SCHEMBL4026767 | 0.81 | ALDH1A1 (0.43) | PLA2G10PLA2G5ALDH1A1KMT2AMEN1 | |
| SCHEMBL4180063 | 0.81 | CTSK (0.43) | PLA2G10PLA2G5ALDH1A1CHRM2CHRM4 | |
| SCHEMBL3885320 | 0.80 | HTR4 (0.38) | HTR4NR3C1 | |
| SCHEMBL28351674 | 0.79 | ALDH1A1 (0.46) | PLA2G10PLA2G5ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112010858-B | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116173232-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116059394-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059201-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| US-5773442-A | EXHIBIT GPIIB/IIIA RECEPTOR ANTAGONISTIC ACTIVITY; USEFUL FOR THE TREATMENT AND PROPHYLAXIS OF VASCULAR SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0810215-A1 | NOVEL BENZAMIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0612313-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993010091-A2 | PIPERIDINE ACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-05-27 | — | — | WO | disclosed |
| EP-0542363-A2 | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | GLAXO GROUP LIMITED (GB) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PLA2G10 4205/4885PLA2G5 3496/4885KDM4E 1013/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PLA2G10 2598/4885PLA2G5 2750/4885KDM4E 1299/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PLA2G10 2598/4885PLA2G5 2750/4885KDM4E 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.